MoonLake Immunotherapeutics CEO Jorge Santos da Silva (L) and CSO Kristian Reich (via website)
MoonLake outlines more data in psoriatic arthritis as it preps for pivotal trials: #AAD24
MoonLake Immunotherapeutics on Sunday touted updated data from a Phase II psoriatic arthritis trial thatwas met with skepticism last year, and has now outlined its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.